8-K: Wellgistics Health Raises $5M, Partners for Diabetes Drug Access

Wellgistics Health completed a $5 million public offering and announced a strategic collaboration with TheracosBio to expand access to an FDA-approved diabetes therapy.

Summary

• Wellgistics Health, Inc. completed a public offering on September 29, 2025, raising approximately $5 million in gross proceeds.
• The offering included the issuance of 7,142,862 shares of common stock and warrants to purchase up to 7,142,862 shares of common stock at a combined public offering price of $0.70 per share and associated warrant.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a cash fee of $350,000, $100,000 for legal fees, $15,950 for clearing expenses, and warrants to purchase up to 500,000 shares of common stock at an exercise price of $0.875.
• Net proceeds from the offering are intended for working capital and general corporate purposes, including operating expenses, research and development, and pending and future acquisitions.
• On September 30, 2025, Wellgistics Health announced a strategic collaboration with TheracosBio to expand nationwide, PBM-free access to Brenzavvy, an FDA-approved Type 2 diabetes therapy.
• This partnership will leverage Wellgistics Health's integrated platform, connecting manufacturers directly to over 6,500 independent pharmacies and participating chain pharmacies to improve affordability and accessibility.
• The integration of Brenzavvy into the Wellgistics Tech & Hub and Distribution platform is scheduled to begin in Q4 2025, with an expected near-term revenue impact.

Sentiment

Score: 8

Explanation: The successful capital raise provides necessary funding, and the strategic partnership with TheracosBio for a high-demand diabetes therapy, coupled with a disruptive distribution model, presents significant growth opportunities and positive market positioning. The expected near-term revenue impact further strengthens the positive outlook, despite the dilution from the offering.

Positives

• Successfully raised approximately $5 million in gross proceeds, strengthening the company's financial position for working capital and strategic initiatives.
• Secured a strategic collaboration with TheracosBio, a pharmaceutical manufacturer, to expand access to an FDA-approved diabetes therapy (Brenzavvy), indicating business expansion.
• The collaboration aims to lower patient costs for diabetes medication, potentially increasing adherence and market penetration for Brenzavvy, addressing a significant market need.
• Leveraging an AI-powered platform for streamlined eligibility, claims, and adherence support enhances operational efficiency and value proposition.
• The Q4 2025 rollout of the TheracosBio partnership is expected to have a near-term revenue impact, suggesting potential for rapid revenue growth.
• The offering was conducted pursuant to an effective registration statement, indicating regulatory compliance and market readiness.

Negatives

• The public offering involved the issuance of new shares and warrants, which could lead to dilution for existing shareholders.
• Significant placement agent fees ($350,000 cash, plus 500,000 warrants) and other offering expenses ($115,950) reduced the net proceeds from the offering.
• The company has not determined the specific allocation of proceeds for operating expenses, R&D, or acquisitions, which could introduce uncertainty regarding future investments.
• Restrictions on future equity sales (70-day lock-up for company/insiders, 6-month restriction on Variable Rate Transactions) limit financial flexibility in the short term.

Risks

• Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from expectations, as noted in the press releases.
• Market conditions, the completion of the offering, and the satisfaction of customary closing conditions related to the offering could impact outcomes.
• The intended use of net proceeds from the offering may not yield the anticipated benefits or may be allocated to less impactful areas.
• Unanticipated factors could arise that cause actual future results to differ materially from forward-looking statements, including operational or market challenges.
• Certain risks regarding the company's forward-looking statements are discussed in its Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which investors should review.

Future Outlook

Wellgistics Health intends to use the net proceeds from the offering for working capital and general corporate purposes, including operating expenses, research and development, and pending and future acquisitions. The strategic collaboration with TheracosBio is expected to integrate Brenzavvy into the Wellgistics Tech & Hub and Distribution platform starting in Q4 2025, positioning the company for near-term revenue impact and aiming to redefine pharmaceutical distribution with increased transparency and affordability.

Management Comments

• "Millions of Americans with type 2 diabetes still face affordability and access barriers at the pharmacy counter. Through Wellgistics Healths streamlined approach, we are expanding access to Brenzavvy, helping patients afford their medications while empowering pharmacists to deliver meaningful care." Brian Connelly, CEO of TheracosBio.
• "Direct-to-patient affordability and access programs are a cornerstone of Wellgistics Healths mission. We are pioneering innovative models designed to not only expand patient access but also bring new levels of transparency and affordability to the healthcare system. By leveraging our technology-enabled platform and our national network of independent and chain pharmacies, we are striving to ensure powerful therapies like Brenzavvy are delivered efficiently, responsibly, and at a cost that patients can sustain." Brian Norton, CEO of Wellgistics Health.

Industry Context

The collaboration between Wellgistics Health and TheracosBio addresses a critical need in the U.S. healthcare system for more affordable and accessible diabetes medications, particularly SGLT-2 inhibitors like Brenzavvy. With Type 2 diabetes affecting over 37 million Americans and incurring significant annual costs, the initiative to bypass traditional PBMs (Pharmacy Benefit Managers) and reduce out-of-pocket expenses aligns with broader industry trends towards greater transparency, cost containment, and direct-to-patient models. This move positions Wellgistics Health as a disruptive force in pharmaceutical distribution, challenging established intermediaries and potentially setting a new standard for drug delivery and patient care.

Comparison to Industry Standards

• The "maker-to-taker" platform directly connecting manufacturers to pharmacies and patients bypasses traditional PBM models, which are often criticized for adding layers of cost and complexity. This contrasts with the standard multi-tiered distribution system involving wholesalers and PBMs.
• The stated goal of lowering costs "often below typical insurance copayments" for Brenzavvy directly challenges the high out-of-pocket costs (exceeding $500 per month) often associated with SGLT-2 inhibitors, a class of drugs where only one in eight eligible adults currently receives treatment.
• Wellgistics Health's network of over 6,500 independent pharmacies and participating chain pharmacies provides a significant distribution reach, comparable to or exceeding the networks of some regional distributors, but with a distinct PBM-agnostic approach.
• The integration of AI-driven modules for eligibility, claims adjudication, and adherence tracking represents an advanced technological approach compared to many traditional pharmaceutical distribution and patient support programs, aiming for greater efficiency and patient outcomes.

Stakeholder Impact

• Shareholders: Potential dilution from the offering, but also potential for increased value from strategic growth and revenue generation through the new partnership.
• Patients: Expected to benefit from expanded access and lower out-of-pocket costs for Brenzavvy, improving medication adherence.
• Pharmacies (Independent & Chain): Participating pharmacies will gain access to Brenzavvy through a direct channel, receive fair compensation, and be empowered with tools for enhanced patient care.
• Employers and Health Plans: Anticipated expedited and transparent savings by bypassing traditional rebate reconciliations.
• Manufacturers (TheracosBio): Gains a direct, efficient channel to reach patients and expand therapy adoption for Brenzavvy.
• Employees: Potential for growth and stability within the company due to new capital and strategic initiatives.

Next Steps

• Integrate Brenzavvy into the Wellgistics Tech & Hub and Distribution platform beginning in Q4 2025.
• Utilize net proceeds for working capital, operating expenses, research and development, and pending/future acquisitions.
• Maintain the listing of Common Stock on the Trading Market and apply to list all Shares and Warrant Shares.
• Comply with lock-up restrictions for the company, executive officers, and directors for specified periods.

Key Dates

Recommendation

The successful $5 million capital raise provides a solid financial foundation for Wellgistics Health's operations and growth initiatives. More significantly, the strategic collaboration with TheracosBio to expand PBM-free access to an FDA-approved diabetes therapy (Brenzavvy) represents a substantial market opportunity. This partnership leverages Wellgistics Health's innovative 'maker-to-taker' platform and AI-driven hub services to address critical issues of affordability and access in the diabetes market, which affects millions of Americans. The expected Q4 2025 rollout and anticipated near-term revenue impact, combined with the company's disruptive approach to pharmaceutical distribution, position Wellgistics Health for strong future performance. While there is some dilution from the offering, the long-term growth prospects and strategic positioning outweigh this short-term factor, making it an attractive investment.

Keywords

Wellgistics Health, WGRX, Public Offering, Capital Raise, Pharmaceutical Distribution, Diabetes Therapy, TheracosBio, Brenzavvy, Healthcare Access, AI-powered Hub Fulfillment, Common Stock, Warrants, SEC Filing, Form 8-K, Equity Offering